Source: ClinicalTrials.gov
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
View on ClinicalTrials.govCitation record
- Study start
- 2024-10-07
- NCT number
- NCT06561386
- Phase
- Phase3
- Overall status
- Recruiting
- Study type
- Interventional
- Lead sponsor
- Bristol-Myers Squibb
- Enrollment
- 1,000 participants
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Nivolumab (Drug) · Relatlimab (Drug) · Pembrolizumab (Drug) · Carboplatin (Drug) · Pemetrexed (Drug) · Cisplatin (Drug)
- Last updated at source
- 23 Oct 2026
- Original source
- https://clinicaltrials.gov/study/NCT06561386
This page reproduces citation metadata only. Inclusion in the Avion Science research library does not imply endorsement and does not establish the safety, efficacy or intended use of any Avion Science compound. Refer to the original record for complete study information.